Xu Feng

7.3k total citations · 3 hit papers
80 papers, 5.9k citations indexed

About

Xu Feng is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Xu Feng has authored 80 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Molecular Biology, 44 papers in Oncology and 18 papers in Cancer Research. Recurrent topics in Xu Feng's work include Bone Metabolism and Diseases (56 papers), Bone health and treatments (38 papers) and NF-κB Signaling Pathways (15 papers). Xu Feng is often cited by papers focused on Bone Metabolism and Diseases (56 papers), Bone health and treatments (38 papers) and NF-κB Signaling Pathways (15 papers). Xu Feng collaborates with scholars based in United States, China and Australia. Xu Feng's co-authors include Jay M. McDonald, Steven L. Teitelbaum, Zhenqi Shi, F. Patrick Ross, Jianzhong Liu, Tim R. Nagy, Xu Cao, Mei Wan, Joel Jules and Deborah V. Novack and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Xu Feng

76 papers receiving 5.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Disorders of Bone Remodeling

2011 974 citations Xu Feng, Jay M. McDonald profile →
TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation

2009 906 citations Yi Tang, Xiangwei Wu et al. Nature Medicine profile →
Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts

2000 563 citations Kevin P. McHugh, Deborah V. Novack et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xu Feng United States	33	4.0k	2.1k	943	835	802	80	5.9k
Joseph Lorenzo United States	43	4.2k 1.0×	2.7k 1.3×	1.2k 1.3×	907 1.1×	1.0k 1.3×	85	6.4k
Hong‐Hee Kim South Korea	41	3.6k 0.9×	1.8k 0.9×	538 0.6×	896 1.1×	840 1.0×	126	5.2k
K. Fuller United Kingdom	40	4.2k 1.0×	2.8k 1.3×	1.2k 1.3×	786 0.9×	553 0.7×	65	6.1k
Masamichi Takami Japan	33	3.4k 0.8×	2.0k 0.9×	647 0.7×	820 1.0×	879 1.1×	110	4.9k
Takuhiko Akatsu Japan	32	4.5k 1.1×	3.4k 1.6×	1.1k 1.1×	735 0.9×	724 0.9×	54	6.3k
Yoshiyuki Hakeda Japan	43	3.4k 0.8×	2.0k 0.9×	735 0.8×	739 0.9×	389 0.5×	89	5.4k
Haibo Zhao United States	39	2.9k 0.7×	1.3k 0.6×	563 0.6×	654 0.8×	458 0.6×	94	4.4k
Nadia Rucci Italy	42	2.7k 0.7×	1.5k 0.7×	494 0.5×	842 1.0×	417 0.5×	107	4.8k
Kurt Redlich Austria	41	3.6k 0.9×	1.9k 0.9×	1.1k 1.2×	910 1.1×	1.4k 1.7×	91	6.8k
Masaki Inada Japan	31	2.1k 0.5×	1.3k 0.6×	456 0.5×	1.3k 1.5×	423 0.5×	90	4.8k

Countries citing papers authored by Xu Feng

Since Specialization

Citations

This map shows the geographic impact of Xu Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xu Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xu Feng more than expected).

Fields of papers citing papers by Xu Feng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xu Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xu Feng. The network helps show where Xu Feng may publish in the future.

Co-authorship network of co-authors of Xu Feng

This figure shows the co-authorship network connecting the top 25 collaborators of Xu Feng. A scholar is included among the top collaborators of Xu Feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xu Feng. Xu Feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shi, Wentao, et al.. (2025). Adverse events associated with IL-23 and IL-12/23 inhibitors in the clinical management of psoriasis: a comprehensive pharmacovigilance analysis. BMC Pharmacology and Toxicology. 26(1). 11–11. 4 indexed citations

Cao, Jinming, Zhicong Chen, Yan Wang, et al.. (2025). Overweight and glucose/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system. Frontiers in Pharmacology. 15. 1517546–1517546.

Zhai, Yinghong, Xiaofei Ye, Wentao Shi, et al.. (2024). Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System. Expert Opinion on Drug Safety. 25(1). 157–165.

Chen, Xuzhuo, Xinwei Chen, Zhihang Zhou, et al.. (2019). AZD8835 inhibits osteoclastogenesis and periodontitis‐induced alveolar bone loss in rats. Journal of Cellular Physiology. 234(7). 10432–10444. 10 indexed citations

Li, Yuyu, Zhenqi Shi, Joel Jules, et al.. (2019). Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis. Journal of Bone and Mineral Research. 34(10). 1938–1951. 18 indexed citations

Feng, Xu. (2013). Identification of Lycopodii Herba by UPLC Fingerprint. Zhongguo shiyan fangjixue zazhi. 2 indexed citations

Cody, James J., Ángel A. Rivera, Minghui Wang, et al.. (2013). Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model. Laboratory Investigation. 93(3). 268–278. 3 indexed citations

Kang, Huicong, Zheng Xue, Furong Wang, et al.. (2013). The Imbalanced Expression of Adenosine Receptors in an Epilepsy Model Corrected Using Targeted Mesenchymal Stem Cell Transplantation. Molecular Neurobiology. 48(3). 921–930. 24 indexed citations

Sawant, Anandi, et al.. (2012). Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer. Cancer Research. 73(2). 672–682. 139 indexed citations

10.

Cheng, Jing, Jianzhong Liu, Zhenqi Shi, et al.. (2011). Molecular Mechanisms of the Biphasic Effects of Interferon-γ on Osteoclastogenesis. Journal of Interferon & Cytokine Research. 32(1). 34–45. 24 indexed citations

11.

Feng, Xu. (2011). Research in Nor-oleanane Triterpenoids. Tianran chanwu yanjiu yu kaifa. 4 indexed citations

12.

Tang, Yi, Xiangwei Wu, Weiqi Lei, et al.. (2009). TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nature Medicine. 15(7). 757–765. 906 indexed citations breakdown →

13.

Wang, Ming, et al.. (2009). [Studies on the chemical constituents of the aerial part of Bupleurum chinense (II)].. PubMed. 32(3). 367–9. 3 indexed citations

14.

Liu, Jianzhong, Shunqing Wang, Ping Zhang, et al.. (2009). Molecular Mechanism of the Bifunctional Role of Lipopolysaccharide in Osteoclastogenesis. Journal of Biological Chemistry. 284(18). 12512–12523. 98 indexed citations

15.

Zhou, Zheng, et al.. (2008). HMGB1 Regulates RANKL-Induced Osteoclastogenesis in a Manner Dependent on RAGE. Journal of Bone and Mineral Research. 23(7). 1084–1096. 128 indexed citations

16.

Chen, Taosheng & Xu Feng. (2006). Cell-Based Assay Strategy for Identification of Motif-Specific RANK Signaling Pathway Inhibitors. Assay and Drug Development Technologies. 4(4). 473–482. 6 indexed citations

17.

Wang, Shunqing, Zhenqi Shi, Wei Liu, Joel Jules, & Xu Feng. (2006). Development and validation of vectors containing multiple siRNA expression cassettes for maximizing the efficiency of gene silencing. BMC Biotechnology. 6(1). 50–50. 28 indexed citations

18.

Liu, Wei, Shunqing Wang, Wei Shi, Li Sun, & Xu Feng. (2005). Receptor Activator of NF-κB (RANK) Cytoplasmic Motif, 369PFQEP373, Plays a Predominant Role in Osteoclast Survival in Part by Activating Akt/PKB and Its Downstream Effector AFX/FOXO4. Journal of Biological Chemistry. 280(52). 43064–43072. 25 indexed citations

19.

Pan, George, Xiaojun Wu, Margaret A. McKenna, et al.. (2004). AZT Enhances Osteoclastogenesis and Bone Loss. AIDS Research and Human Retroviruses. 20(6). 608–620. 45 indexed citations

20.

Feng, Xu, Deborah V. Novack, Roberta Faccio, et al.. (2001). A Glanzmann’s mutation in β3 integrin specifically impairs osteoclast function. Journal of Clinical Investigation. 107(9). 1137–1144. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact